The future of the global primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets. The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the primary immunodeficiency
therapeutics market by type (immunoglobulin replacement therapy, stem cell/bone
marrow transplantation, antibiotic therapy, gene therapy, and others), disease
type (antibody deficiency, cellular immunodeficiency, innate immune disorders,
and others), and region (North America, Europe, Asia Pacific, and the Rest of
the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by disease type or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, antibody
deficiency, cellular immunodeficiency, and innate immune disorders are the major
segments of primary immunodeficiency therapeutics market by disease type.
Lucintel forecasts that antibody deficiency will remain the largest segment due
to increasing awareness of antibody deficiency and aging population is more
susceptible to antibody deficiency.
Within this market,
immunoglobulin replacement therapy is expected to remain the largest segment as
it helps to improve the immune system function and also reduces the risk of
infections in primary immunodeficiency disorders patients.
North America will
remain the largest segment due to high prevalence of primary immunodeficiency
disorders and availability of reimbursement for primary immunodeficiency
disorders therapeutics.
Pfizer, CSL Behring,
Grifols, Abbott, Adma Biologics, Astrazeneca, Baxter, Bayer, Biocon, and
Bristol-Myers Squibb are the major suppliers in the primary immunodeficiency
therapeutics market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment